The Medical Advisor

We are pleased to announce that the first-of-its-kind protocol utilizing Ivermectin, Mebendazole, and Fenbendazole for cancer treatment has been peer-reviewed and officially published on September 19, 2024. Spearheaded by leading researchers like Dr. Ilyes Baghli, Dr. Pierrick Martinez, and the FLCCC’s Dr. Paul Marik, this groundbreaking protocol harnesses the untapped power of Ivermectin, Mebendazole, and Fenbendazole, known for their effectiveness against parasites. Now, these drugs are showing potential to battle cancer, marking the dawn of a new treatment evolution. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondri...

Our diets can both feed and starve cancer cells’ productivity by affecting multiple mechanisms that promote cancer. Cancer cells rely on the ability to multiply, repair, differentiate, and evade apoptosis (programmed cell death). The recent discovery of cancer stem cells has scientists looking at a whole new approach to preventing and treating cancer. Cancer stem cells have a pro-survival strategy involved in promoting cancer cell invasion, growth, and metastasis ( 9 ). These cancer stem cells are unlike typical stem cells because they are designed to promote cancerous activities including: ( 4 ,  12 ) The ability to self-renew. Resistant to chemotherapeutic drugs Self-sufficient Not influenced by anti-growth signals or by contact with other stem cells Not regulated by normal cell functions including apoptosis Promote inflammation. Regulated by tissue invasion and metastasis. Sustained by angiogenesis and flawed cellular energy. Fortunately, cancer stem cells are affected by phytoc...

Researchers delving into the timing of subsequent colonoscopies found that for some people, the risks are no different if they wait 15 years instead of 10. The invasive and expensive nature of colonoscopies makes determining how to maximize their usefulness—particularly when it comes to follow-up screenings—a prominent topic of research. It’s undisputed that the surgical-based test can save lives, but the timing remains a moving target. Three years ago, the U.S. Preventive Services Task Force lowered the recommended age for the first colorectal cancer screening by five years—from 50 years of age to 45. Now, the gap between the first and second tests is being scrutinized. Long-term data used in a JAMA Oncology study published May 2, 2024 suggests it may be time to move the follow-up screening back five years in certain circumstances. Specifically, the study indicates that anyone who doesn’t have a family history of colorectal cancer and whose first colonoscopy was free of polyps—abnorm...